GlobeNewswire: Medigene AG Contains the last 10 of 81 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T10:28:33ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/28/2853715/0/en/Medigene-AG-Reports-Full-Year-2023-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=30196Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update2024-03-28T06:30:00Z<![CDATA[Planegg/Martinsried, March 28, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today reported financial results for the fiscal year ended December 31, 2023, and provided a corporate update.]]>https://www.globenewswire.com/news-release/2024/03/19/2848591/0/en/Medigene-AG-to-participate-in-the-H-C-Wainwright-2nd-Annual-Cell-Therapy-Virtual-Conference.html?f=22&fvtc=4&fvtv=30196Medigene AG to participate in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference2024-03-19T13:00:00Z<![CDATA[Planegg/Martinsried, March 19, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be participating in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on March 26, 2024.]]>https://www.globenewswire.com/news-release/2024/03/18/2847904/0/en/Medigene-AG-to-report-full-year-2023-financial-results-on-March-28-2024.html?f=22&fvtc=4&fvtv=30196Medigene AG to report full year 2023 financial results on March 28, 20242024-03-18T14:00:00Z<![CDATA[Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will report financial results and provide a corporate update for the fiscal year ended December 31, 2023, on Thursday, March 28, 2024.]]>https://www.globenewswire.com/news-release/2024/03/06/2841155/0/en/Medigene-to-Present-Favorable-Safety-Profile-of-TCR-T-Cells-upon-Addition-of-Costimulatory-Switch-Protein-with-a-Poster-Presentation-at-AACR-2024-Annual-Meeting.html?f=22&fvtc=4&fvtv=30196Medigene to Present Favorable Safety Profile of TCR-T Cells upon Addition of Costimulatory Switch Protein with a Poster Presentation at AACR 2024 Annual Meeting 2024-03-06T10:00:00Z<![CDATA[Planegg/Martinsried, March 6, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present a poster at the American Association for Cancer Research Annual Meeting (AACR) 2024 taking place from April 5-10, 2024 in San Diego, USA as well as an oral presentation at the ELRIG-Forum 2024 to be held in Darmstadt, Germany on March 7, 2024.]]>https://www.globenewswire.com/news-release/2024/03/04/2839238/0/en/Medigene-AG-Expands-Patent-Portfolio-in-Japan-for-iM-TCR-Technology-to-Directly-Control-TCR-T-Safety-and-Efficacy-In-Vivo.html?f=22&fvtc=4&fvtv=30196Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy, In Vivo2024-03-04T07:00:00Z<![CDATA[Planegg/Martinsried, March 4, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced that the Company has been issued a patent by the Japan Patent Office protecting its inducible Medigene T cell receptor (iM-TCR), a control mechanism to regulate efficacy and safety of its T cell receptor engineered T cell (TCR-T) therapies.]]>https://www.globenewswire.com/news-release/2024/02/29/2837769/0/en/Medigene-Presents-at-CAR-TCR-Summit-Europe-Showcasing-Unique-Approach-for-Development-of-Differentiated-TCR-T-Therapies.html?f=22&fvtc=4&fvtv=30196Medigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach for Development of Differentiated TCR-T Therapies 2024-02-29T11:00:00Z<![CDATA[Planegg/Martinsried, February 29, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today highlighted recent updates on the progress made within key areas of its proprietary End-to-End Platform, at the 7th CAR-TCR Summit Europe taking place in London from February 27-29, 2024.]]>https://www.globenewswire.com/news-release/2024/02/19/2831266/0/en/Medigene-to-Present-at-Upcoming-Conferences.html?f=22&fvtc=4&fvtv=30196Medigene to Present at Upcoming Conferences2024-02-19T13:00:00Z<![CDATA[Planegg/Martinsried, February 19, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present at the 7th CAR-TCR Summit Europe taking place February 27-29, 2024, in London as well as at the East-West Biopharma Summit to be held March 4-6, 2024, in Singapore.]]>https://www.globenewswire.com/news-release/2024/02/12/2827472/0/en/Medigene-Announces-Indication-Selection-for-the-Clinical-Development-of-its-Lead-3rd-Generation-TCR-T-Therapy-Program-in-Solid-Tumors.html?f=22&fvtc=4&fvtv=30196Medigene Announces Indication Selection for the Clinical Development of its Lead 3rd Generation TCR-T Therapy Program in Solid Tumors2024-02-12T13:00:00Z<![CDATA[Planegg/Martinsried, February 12, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced the selection of gastric cancer, ovarian cancer and two types of soft tissue sarcomas, myxoid/round cell liposarcoma and synovial sarcoma, as the initial clinical indications for its lead candidate MDG1015. MDG1015 is a first-in-class, third generation T cell receptor engineered T cell (TCR-T) therapy targeting NY-ESO-1/LAGE-1a (New York esophageal squamous cell carcinoma 1 / L Antigen Family Member-1a), armored and enhanced by costimulatory switch protein PD1-41BB in the context of HLA-A*02 (HLA, human leukocyte antigen). Preclinical data presented in 2023 at the AACR and ESMO conferences demonstrated the clear potential of MDG1015 to improve clinical outcomes in solid tumors.]]>https://www.globenewswire.com/news-release/2023/12/19/2798480/0/en/Medigene-AG-to-attend-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html?f=22&fvtc=4&fvtv=30196Medigene AG to attend at the 42nd Annual J.P. Morgan Healthcare Conference2023-12-19T13:00:00Z<![CDATA[Planegg/Martinsried, December 19, 2023. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be attending the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco to be held from January 8-11, 2024.]]>https://www.globenewswire.com/news-release/2023/11/21/2784296/0/en/Medigene-AG-Announces-Prioritization-of-Pipeline-and-Resource-Allocation-as-well-as-Extension-of-Cash-Runway.html?f=22&fvtc=4&fvtv=30196 Medigene AG Announces Prioritization of Pipeline and Resource Allocation as well as Extension of Cash Runway 2023-11-21T17:05:00Z<![CDATA[Planegg/Martinsried, November 21, 2023. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced an update and prioritization of its pipeline and resource allocation to support the execution of its long-term corporate strategy.]]>